Nav: Home

CNIO researchers identify a new gene involved in the development of a rare endocrine tumour

March 28, 2019

Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases per million inhabitants worldwide. They are also the most inheritable types of tumours: whereas, in general terms, cancer is only 5-10% inherited, 35-40% of paragangliomas are hereditary. It is known that many of these tumours are caused by mutations in various genes involved in the Krebs cycle, the process by which cells breathe and get energy. Now, researchers from the Hereditary Endocrine Cancer Group at the Spanish National Cancer Research Centre (CNIO) have discovered that another gene involved in this cycle, DLST, gives rise to the disease when it is mutated. In addition to the therapeutic implications this may have in the future, the finding will broaden the number of families susceptible to these tumours who could benefit from prevention, early detection and monitoring programmes. The paper is published in The American Journal of Human Genetics.

Paragangliomas are tumours of the paraganglia, groups of cells in the nervous system that are distributed around the head, neck, chest and abdomen. Phaeochromocytomas are paragangliomas found in the adrenal glands. "Those of us who study these tumours classify them as the same disease," says Alberto Cascón, a researcher at the CNIO Hereditary Endocrine Cancer Group and lead author of the paper. The symptoms are non-specific and include high blood pressure, headache, profuse sweating, instability and extreme paleness, so patients often go through numerous specialists before getting the correct diagnosis, which is usually made by an endocrinologist using imaging technologies or detecting high levels of catecholamines -hormones produced by the adrenal glands such as adrenaline- in the urine or blood.

Defects in cellular respiration

About half of these cancers are caused by mutations in genes involved in the Krebs cycle. This cycle is a fundamental metabolic pathway for cells and constitutes one of the stages in their breathing, through which they obtain energy. This process, which is essential for life, includes a series of chemical reactions carried out by enzymes produced by a relatively small number of genes. Mutations in several of these genes give rise to paragangliomas and phaeochromocytomas.

"For our study, we started from the premise that the Krebs cycle is directly linked to the disease," explains Cascón. "So we decided to sequence all the genes involved in this cycle, in order to see if we could detect any new ones causing paragangliomas/phaeochromocytomas that we had not known about previously."

The investigation found that 8 non-related patients showed mutations in the DLST gene, 4 of them with a specific mutation that was shown to directly affect the development of the disease. "This is the first time this gene has been linked with cancer." This gene has already been included in the diagnostic panel for the early detection of the disease.

Mutations in the cycle genes tend to be germinal, which means they are inherited from one of the patient's parents, so that all their cells have the mutation. This also implies that the Krebs cycle has a functional fault in all cells of these patients. When a tumour has been removed by surgery, the patients require close clinical monitoring, as there is a high probability that they will develop more tumours throughout their life.

The importance of family monitoring

Surgery is the main treatment for paraganglioma and phaeochromocytoma, together with appropriate clinical monitoring.

"Apart from surgery, there is no treatment approved by the European or American agencies," explains Mercedes Robledo, Head of the CNIO Hereditary Endocrine Cancer Group and Head of the Group U706 at the Centre for Biomedical Network Research on Rare Diseases (CIBERER). "Therefore, in order to be able to search for therapies, it is very important to discover all the genes and molecular pathways involved in the disease. Once this has been done, our role is to determine which patients have mutations in which gene and could benefit from specific treatments developed in the future." Furthermore, therapies that have already been approved for other diseases could well be valid in such cases. "But because they are such rare diseases, first you have to classify patients extremely carefully before trying to see if there are already appropriate therapies for them. Moreover, a fundamental part of our job is to ensure all our clinical data are kept up to date, to know whether being a carrier of a mutation in the new genes also implies an increased risk of developing other tumours."

Leaving therapies aside for a moment, and bearing in mind that these tumours are the most hereditary type of cancer, the identification of new genes is invaluable in terms of providing a diagnosis for the entire family of a patient in which a mutation has been identified. That is the only way tumours can be detected in time. Therefore, the group led by Robledo has been collecting since 1996 a large registry of Spanish patients to study these diseases, which integrates around 800 index patients (between families and individual cases) and that is the largest registry of patient samples of this disease in our country today. In addition, the team has become a reference for its genetic diagnosis, not only in Spain but also internationally: "We receive samples from Germany, Italy ... but also from outside Europe, such as the United States or Canada," notes Robledo.

"Once one of these mutations has been detected in a person, because it is likely to be present in another member of the family, the whole process of a family-wide study begins," explains Miguel Urioste, Head of the CNIO Familial Cancer Clinical Unit, which since 2001 has provided genetic counselling to almost 6,000 patients with family cancers. "There are two factors to keep in mind: on the one hand, penetrance, that is to say, knowing which percentage of people who have the mutated gene develop the disease; and, on the other hand, if there is a risk of developing another type of tumour. In the case of DLST, as this is the first time it has been linked with cancer, these data are not yet known."

Another as yet unresolved enigma is why DLST behaves differently to other Krebs cycle genes in the disease. In general terms, 20% of patients with phaeochromocytoma or paraganglioma will develop metastatic disease. Patients with mutations in this cycle have an increased risk of developing metastases because such mutations cause alterations in the expression of many other genes, including some related to processes of invasion. However, DLST does not exhibit this behaviour.

To settle these and other unresolved issues, further studies will be required. Mercedes Robledo said, "We will present a proposal to the ENS@T European network for the study of adrenal tumours to study the gene at a global level." She leads the working group for paraganglioma/phaeochromocytoma that is a part of this network.
This is a transversal project within CNIO, which also involved the Structural Biology Programme, the Human Genotyping-CEGEN Unit, the Monoclonal Antibodies Core Unit and the Familial Cancer Clinical Unit, as well as the CIBERER, the Hospital de León, the Hospital Universitario Puerta de Hierro (Madrid), the Technical University of Dresden (Germany) and Agios Pharmaceuticals.

The study was funded by the Spain's Instituto de Salud Carlos III, the European Regional Development Fund, and the Deutsche Forschungsgemeinschaft.

Reference article: Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Laura Remacha et al (The American Journal of Human Genetics, 2019). DOI:

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at